Trial · NCT00413413
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 15 of 15
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8) | Valsartan/Amlodipine 80/5 mg | -10.8 | Standard Error 0.42 | mmHg | |
| Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8) | Valsartan 80 mg | -6.3 | Standard Error 0.42 | mmHg | |
| Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8) | Valsartan 160 mg | -7.2 | Standard Error 0.42 | mmHg | |
| Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8) | Valsartan/Amlodipine 80/5 mg | -12.5 | Standard Error 0.61 | mmHg | |
| Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8) | Valsartan 80 mg | -6.0 | Standard Error 0.62 | mmHg | |
| Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8) | Valsartan 160 mg | -7.7 | Standard Error 0.62 | mmHg | |
| Percentage of Patients Achieving a Diastolic Blood Pressure Response at the End of the Study (Week 8) | Valsartan/Amlodipine 80/5 mg | 77.9 | Percentage of patients | ||
| Percentage of Patients Achieving a Diastolic Blood Pressure Response at the End of the Study (Week 8) | Valsartan 80 mg | 57.8 | Percentage of patients | ||
| Percentage of Patients Achieving a Diastolic Blood Pressure Response at the End of the Study (Week 8) | Valsartan 160 mg | 66.6 | Percentage of patients | ||
| Percentage of Patients Achieving Diastolic Blood Pressure Control at the End of the Study (Week 8) | Valsartan/Amlodipine 80/5 mg | 74.4 | Percentage of patients | ||
| Percentage of Patients Achieving Diastolic Blood Pressure Control at the End of the Study (Week 8) | Valsartan 80 mg | 53.6 | Percentage of patients | ||
| Percentage of Patients Achieving Diastolic Blood Pressure Control at the End of the Study (Week 8) | Valsartan 160 mg | 64.2 | Percentage of patients | ||
| Percentage of Patients Achieving Overall Blood Pressure Control at the End of the Study (Week 8) | Valsartan/Amlodipine 80/5 mg | 70.5 | Percentage of patients | ||
| Percentage of Patients Achieving Overall Blood Pressure Control at the End of the Study (Week 8) | Valsartan 80 mg | 44.1 | Percentage of patients | ||
| Percentage of Patients Achieving Overall Blood Pressure Control at the End of the Study (Week 8) | Valsartan 160 mg | 58.6 | Percentage of patients |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00413413/results